RxDoctor Payments Data

Lindsey Kerr, MD

Urology · Rockport, MENPI 1326138926

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 27.0% of the total. Reporting peaked in 2020 at $523 and has fallen 62.5% since, to $196 in 2025.

$1,618in general payments, 2019–2025

Across 41 payments — averaging $39.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$437
  • Coloplast$215
  • Procept Biorobotics Corporation$165
  • Dornier Medtech America, Inc$125
  • Astellas Pharma US Inc$110
  • Boston Scientific$104
  • plus $461 from 13 others

What the payments were for

  • Food & beverage$1,54395%
  • Education$755%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)12$437
Coloplast5$215
Procept Biorobotics Corporation1$165
Dornier Medtech America, Inc1$125
Astellas Pharma US Inc4$110
Boston Scientific1$104
Laborie Medical Technologies Corp.1$80
Rochester Medical Corporation2$71
Urogen Pharma, Inc.1$51
Teleflex LLC1$47
Myovant Sciences Inc.2$38
Axonics, Inc.2$31
Johnson & Johnson2$28
Intuitive Surgical1$27
Ambu Inc.1$23
Bayer1$21
Tolmar, Inc.1$19
Olympus America Inc.1$13
180 Medical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,618 in reported general payments places this provider in the 60th percentile of 59 urology providers in Maine.

See all urology providers in Maine

Medicare billing

Part B allowed, 2024
$2,128
Medicare patients
22
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron14$8,085
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$592
Oxybutynin Chloride ErOxybutynin Chloride18$314
Tamsulosin Hcl15$75
Finasteride15$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$110$8,08514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 59 urology providers in Maine.

Other urology in Rockport

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →